Assessing the interplay between off-target promiscuity, cytotoxicity, and tolerability in rodents to improve the safety profile of novel anti-malarial plasmepsin X inhibitors.

Autor: Gerets HHJ; UCB Biopharma SRL, 1420 Braine-l'Alleud, Belgium., Delaunois A; UCB Biopharma SRL, 1420 Braine-l'Alleud, Belgium., Cardenas A; UCB Biopharma SRL, 1420 Braine-l'Alleud, Belgium., Class R; UCB Biopharma SRL, 1420 Braine-l'Alleud, Belgium., Fleurance R; UCB Biopharma SRL, 1420 Braine-l'Alleud, Belgium., de Haro T; UCB Biopharma SRL, 1420 Braine-l'Alleud, Belgium., Laleu B; MMV Medicines for Malaria Venture, ICC, 1215 Geneva, Switzerland., Lowe MA; UK Branch of UCB Pharma, SL1 3WE Slough, United Kingdom., Rosseels ML; UCB Biopharma SRL, 1420 Braine-l'Alleud, Belgium., Valentin JP; UCB Biopharma SRL, 1420 Braine-l'Alleud, Belgium.

Publikováno v: Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2024 Oct 01; Vol. 201 (2), pp. 311-320.

Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of UCB7362 .

Autor: Lowe MA; UCB, 216 Bath Road, Slough SL1 3WE, United Kingdom., Cardenas A; UCB, Chem. du Foriest 1, 1420 Braine-l'Alleud, Belgium., Valentin JP; UCB, Chem. du Foriest 1, 1420 Braine-l'Alleud, Belgium., Zhu Z; UCB, 216 Bath Road, Slough SL1 3WE, United Kingdom., Abendroth J; UCB, 7869 NE Day Road West, Bainbridge Island, Washington 98110, United States., Castro JL; UCB, 216 Bath Road, Slough SL1 3WE, United Kingdom., Class R; UCB, Chem. du Foriest 1, 1420 Braine-l'Alleud, Belgium., Delaunois A; UCB, Chem. du Foriest 1, 1420 Braine-l'Alleud, Belgium., Fleurance R; UCB, Chem. du Foriest 1, 1420 Braine-l'Alleud, Belgium., Gerets H; UCB, Chem. du Foriest 1, 1420 Braine-l'Alleud, Belgium., Gryshkova V; UCB, Chem. du Foriest 1, 1420 Braine-l'Alleud, Belgium., King L; UCB, 216 Bath Road, Slough SL1 3WE, United Kingdom., Lorimer DD; UCB, 7869 NE Day Road West, Bainbridge Island, Washington 98110, United States., MacCoss M; Bohicket Pharma Consulting LLC, 2556 Seabrook Island Road, Seabrook Island, South Carolina 29455, United States., Rowley JH; UCB, 216 Bath Road, Slough SL1 3WE, United Kingdom., Rosseels ML; UCB, Chem. du Foriest 1, 1420 Braine-l'Alleud, Belgium., Royer L; UCB, Chem. du Foriest 1, 1420 Braine-l'Alleud, Belgium., Taylor RD; UCB, 216 Bath Road, Slough SL1 3WE, United Kingdom., Wong M; UCB, 216 Bath Road, Slough SL1 3WE, United Kingdom., Zaccheo O; UCB, 216 Bath Road, Slough SL1 3WE, United Kingdom., Chavan VP; Sai Life Sciences Limited, Plot DS-7, IKP Knowledge Park, Genome Valley, Turkapally, Hyderabad 500078, Telangana, India., Ghule GA; Sai Life Sciences Limited, Plot DS-7, IKP Knowledge Park, Genome Valley, Turkapally, Hyderabad 500078, Telangana, India., Tapkir BK; Sai Life Sciences Limited, Plot DS-7, IKP Knowledge Park, Genome Valley, Turkapally, Hyderabad 500078, Telangana, India., Burrows JN; Medicines for Malaria Venture, ICC, Route de Pré-Bois 20, 1215 Geneva, Switzerland., Duffey M; Medicines for Malaria Venture, ICC, Route de Pré-Bois 20, 1215 Geneva, Switzerland., Rottmann M; Swiss Tropical and Public Health Institute, Kreuzstrasse 2, CH-4123 Allschwil, Switzerland.; University of Basel, 4002 Basel, Switzerland., Wittlin S; Swiss Tropical and Public Health Institute, Kreuzstrasse 2, CH-4123 Allschwil, Switzerland.; University of Basel, 4002 Basel, Switzerland., Angulo-Barturen I; The Art of Discovery, SL Biscay Science and Technology Park, Astondo Bidea, BIC Bizkaia Building, no. 612, Derio 48160, Bizkaia, Basque Country, Spain., Jiménez-Díaz MB; The Art of Discovery, SL Biscay Science and Technology Park, Astondo Bidea, BIC Bizkaia Building, no. 612, Derio 48160, Bizkaia, Basque Country, Spain., Striepen J; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States., Fairhurst KJ; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States., Yeo T; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States., Fidock DA; Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States.; Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, New York 10032, United States., Cowman AF; The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia., Favuzza P; The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia., Crespo-Fernandez B; Global Health, GlaxoSmithKline R&D, Tres Cantos, 28760 Madrid, Spain., Gamo FJ; Global Health, GlaxoSmithKline R&D, Tres Cantos, 28760 Madrid, Spain., Goldberg DE; Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8051, St. Louis, Missouri 63110, United States., Soldati-Favre D; Department of Microbiology and Molecular Medicine, Faculty of Medicine, CMU, 1 rue Michel-Servet, CH-1211 Genève 4, Switzerland., Laleu B; Medicines for Malaria Venture, ICC, Route de Pré-Bois 20, 1215 Geneva, Switzerland., de Haro T; UCB, Chem. du Foriest 1, 1420 Braine-l'Alleud, Belgium.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2022 Oct 27; Vol. 65 (20), pp. 14121-14143. Date of Electronic Publication: 2022 Oct 10.

Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions.

Autor: Nicolas JM; UCB BioPharma SPRL, Chemin du Foriest, B-1420 Braine l'Alleud, Belgium. Electronic address: Jean-Marie.Nicolas@ucb.com., Chanteux H; UCB BioPharma SPRL, Chemin du Foriest, B-1420 Braine l'Alleud, Belgium., Nicolaï J; UCB BioPharma SPRL, Chemin du Foriest, B-1420 Braine l'Alleud, Belgium., Brouta F; UCB BioPharma SPRL, Chemin du Foriest, B-1420 Braine l'Alleud, Belgium., Viot D; UCB BioPharma SPRL, Chemin du Foriest, B-1420 Braine l'Alleud, Belgium., Rosseels ML; UCB BioPharma SPRL, Chemin du Foriest, B-1420 Braine l'Alleud, Belgium., Gillent E; UCB BioPharma SPRL, Chemin du Foriest, B-1420 Braine l'Alleud, Belgium., Bonnaillie P; UCB BioPharma SPRL, Chemin du Foriest, B-1420 Braine l'Alleud, Belgium., Mathy FX; UCB BioPharma SPRL, Chemin du Foriest, B-1420 Braine l'Alleud, Belgium., Long J; UCB BioPharma SPRL, Chemin du Foriest, B-1420 Braine l'Alleud, Belgium., Helmer E; Galapagos Biotech Limited, Cambridge, UK.

Publikováno v: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2020 Jan 15; Vol. 142, pp. 105122. Date of Electronic Publication: 2019 Oct 31.

Renal Safety Pharmacology in Drug Discovery and Development.

Autor: Benjamin A; Drug Safety and Metabolism, AstraZeneca, Alderley Park, Cheshire, SK10-4TG, UK., Nogueira da Costa A, Delaunois A, Rosseels ML, Valentin JP

Publikováno v: Handbook of experimental pharmacology [Handb Exp Pharmacol] 2015; Vol. 229, pp. 323-52.

Hydroxypropyl-β-cyclodextrin impacts renal and systemic hemodynamics in the anesthetized dog.

Autor: Rosseels ML; Non-Clinical Safety Evaluation, UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium. Electronic address: marie-luce.rosseels@ucb.com., Delaunois AG, Hanon E, Guillaume PJ, Martin FD, van den Dobbelsteen DJ

Publikováno v: Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2013 Dec; Vol. 67 (3), pp. 351-9. Date of Electronic Publication: 2013 Aug 23.